DAROLUTAMIDE PLUS ANDROGEN DEPRIVATION THERAPY (ADT) IN METASTATIC HORMONE-SENSITIVE PROSTATE CANCER (MHSPC): ARASEC – US PROSPECTIVE, OPEN-LABEL PHASE 2 STUDY WITH AN EXTERNAL CONTROL ARM
This research output has an Altmetric Attention Score of 12. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 15 July 2026.
All research outputs
#3,680,654
of 33,738,238 outputs
Outputs from The Journal of Urology
#2,404
of 21,677 outputs
Outputs of similar age
#33,189
of 361,793 outputs
Outputs of similar age from The Journal of Urology
#18
of 80 outputs
Altmetric has tracked 33,738,238 research outputs across all sources so far. Compared to these this one has done well and is in the 88th percentile: it's in the top 25% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 21,677 research outputs from this source. They typically receive more attention than average, with a mean Attention Score of 9.6. This one has done well, scoring higher than 87% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 361,793 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 90% of its contemporaries.
We're also able to compare this research output to 80 others from the same source and published within six weeks on either side of this one. This one has done well, scoring higher than 77% of its contemporaries.
